Company intelligence / Profile preview

daacro

Trier, Rhineland-Palatinate, Germany

Ownership: Private
Development stage: Other

Overview

daacro is a CRO specializing in phase I-IV clinical trials with expertise in psychotropic drug assessment and stress-related diagnostics via its neuropattern™ platform. The company participated in the EU-funded “ActiveNutraLife” project to develop complementary medicine approaches for post-chemotherapy recovery in hematological cancer patients, with a focus on biomarker development and personalized management.

Therapeutic areas: OncologyNeurologyPsychiatry
Modalities: Diagnostic platformClinical researchSmall moleculeDiagnostic device
Industry: Contract Research Organization

Partnerships

Salimetrics (lab technology and biomarker analytics)Bionov (nutraceuticals, ActiveNutraLife project)V@si (physical activity, ActiveNutraLife project)

Beyond the preview

Go deeper on daacro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on daacro.

Explore the full profile